Denali Therapeutics Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Denali Therapeutics Inc. (DNLI) reported Increase (Decrease) in Prepaid Expense and Other Assets of $2.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- Denali Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $322.00K.
- Denali Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $2.29M, a 91.99% decline year-over-year.
- Denali Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$1.75M.
- Denali Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$1.36M.
- Denali Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $540.00K, a 78.23% decline from fiscal 2024.
- Denali Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $2.48M, a 39.42% decline from fiscal 2023.
- Denali Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $4.09M, a 48.33% increase from fiscal 2022.
- Denali Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $2.76M, a 78.55% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $322.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.61M 10-Q · filed 2026-08-06 | $866.00K derived: sum of 3 quarters · filed 2026-08-06 | -$497.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.29M 10-Q · filed 2026-05-07 | $544.00K derived: sum of 2 quarters · filed 2026-05-07 | -$819.00K derived: sum of 3 quarters · filed 2026-05-07 | -$25.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.11M derived: sum of 2 quarters · filed 2026-02-26 | -$28.07M derived: sum of 3 quarters · filed 2026-08-06 | $540.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$26.32M derived: sum of 2 quarters · filed 2026-08-06 | $2.29M 10-Q · filed 2025-11-06 | $2.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$24.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.65M 10-Q · filed 2026-08-06 | $3.50M derived: sum of 3 quarters · filed 2026-08-06 | -$14.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $28.61M 10-Q · filed 2026-05-07 | $28.46M derived: sum of 2 quarters · filed 2026-05-07 | $10.75M derived: sum of 3 quarters · filed 2026-05-07 | $12.32M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$17.86M derived: sum of 2 quarters · filed 2026-02-26 | -$16.29M derived: sum of 3 quarters · filed 2026-02-26 | $2.48M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$17.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$16.14M derived: sum of 2 quarters · filed 2025-11-06 | $2.63M 10-Q · filed 2025-11-06 | $8.63M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $20.34M 10-Q · filed 2025-08-11 | $26.34M derived: sum of 3 quarters · filed 2026-02-26 | $26.25M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $18.77M 10-Q · filed 2025-05-06 | $24.77M derived: sum of 2 quarters · filed 2026-02-26 | $24.68M derived: sum of 3 quarters · filed 2026-02-26 | $21.07M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.92M derived: sum of 2 quarters · filed 2026-02-26 | $2.31M derived: sum of 3 quarters · filed 2026-02-26 | $4.09M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$87.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$3.70M derived: sum of 2 quarters · filed 2024-11-06 | -$1.91M 10-Q · filed 2024-11-06 | -$536.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$3.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$1.82M 10-Q · filed 2024-08-01 | -$449.00K derived: sum of 3 quarters · filed 2025-02-27 | -$13.81M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.79M 10-Q · filed 2024-05-07 | $3.16M derived: sum of 2 quarters · filed 2025-02-27 | -$10.20M derived: sum of 3 quarters · filed 2025-02-27 | $5.79M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$11.99M derived: sum of 2 quarters · filed 2025-02-27 | $4.00M derived: sum of 3 quarters · filed 2025-02-27 | $2.76M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$13.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $2.63M derived: sum of 2 quarters · filed 2023-11-07 | $1.39M 10-Q · filed 2023-11-07 | $22.30M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $15.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $14.75M 10-Q · filed 2023-08-08 | $35.66M derived: sum of 3 quarters · filed 2024-02-28 | $19.56M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$1.24M 10-Q · filed 2023-05-08 | $19.67M derived: sum of 2 quarters · filed 2024-02-28 | $3.57M derived: sum of 3 quarters · filed 2024-02-28 | $17.92M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $20.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $4.81M derived: sum of 2 quarters · filed 2024-02-28 | $19.17M derived: sum of 3 quarters · filed 2024-02-28 | $12.87M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$16.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$1.75M derived: sum of 2 quarters · filed 2022-11-03 | -$8.05M 10-Q · filed 2022-11-03 | $6.34M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $14.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $8.05M 10-Q · filed 2022-08-08 | $22.44M derived: sum of 3 quarters · filed 2023-02-27 | $22.42M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$6.30M 10-Q · filed 2022-05-05 | $8.09M derived: sum of 2 quarters · filed 2023-02-27 | $8.06M derived: sum of 3 quarters · filed 2023-02-27 | $1.81M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $14.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $14.36M derived: sum of 2 quarters · filed 2023-02-27 | $8.12M derived: sum of 3 quarters · filed 2023-02-27 | $10.57M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$6.27M derived: sum of 2 quarters · filed 2021-11-04 | -$3.82M 10-Q · filed 2021-11-04 | -$4.68M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$6.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$3.79M 10-Q · filed 2021-08-04 | -$4.66M derived: sum of 3 quarters · filed 2022-02-28 | -$7.76M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $2.45M 10-Q · filed 2021-05-05 | $1.59M derived: sum of 2 quarters · filed 2022-02-28 | -$1.52M derived: sum of 3 quarters · filed 2022-02-28 | -$1.37M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$863.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$3.97M derived: sum of 2 quarters · filed 2022-02-28 | -$3.83M derived: sum of 3 quarters · filed 2022-02-28 | -$6.67M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$3.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$2.96M derived: sum of 2 quarters · filed 2020-11-05 | -$5.81M 10-Q · filed 2020-11-05 | $7.10M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $145.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$2.70M 10-Q · filed 2020-08-07 | $10.21M derived: sum of 3 quarters · filed 2021-02-26 | $13.87M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$2.85M 10-Q · filed 2020-05-07 | $10.06M derived: sum of 2 quarters · filed 2021-02-26 | $13.72M derived: sum of 3 quarters · filed 2021-02-26 | $13.83M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $12.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $16.57M derived: sum of 2 quarters · filed 2021-02-26 | $16.68M derived: sum of 3 quarters · filed 2021-02-26 | $18.29M 10-K · filed 2021-02-26 |
| 2018-09-30 | $3.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $3.77M derived: sum of 2 quarters · filed 2019-11-06 | $5.38M 10-Q · filed 2019-11-06 | $5.30M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $105.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.72M 10-Q · filed 2019-08-06 | $1.64M derived: sum of 3 quarters · filed 2020-02-27 | $2.91M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $1.61M 10-Q · filed 2019-05-08 | $1.54M derived: sum of 2 quarters · filed 2020-02-27 | $2.81M derived: sum of 3 quarters · filed 2020-02-27 | $3.50M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | -$76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $1.19M derived: sum of 2 quarters · filed 2020-02-27 | $1.89M derived: sum of 3 quarters · filed 2020-02-27 | -$73.00K 10-K · filed 2020-02-27 |
| 2017-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.96M derived: sum of 2 quarters · filed 2018-11-08 | $3.00K 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $693.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$1.27M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | -$1.96M 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $533.00K 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |